Evidence map›Paper›PMID 34355087›Full record

ArticleHeliyon2021

Inclusion complexation of the anticancer drug pomalidomide with cyclodextrins: fast dissolution and improved solubility.

Zoltán-István Szabó, György Orbán, Enikő Borbás, Dóra Csicsák, Szabina Kádár, Béla Fiser, Máté Dobó, Péter Horváth, Eszter Kiss, Lívia Budai and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 3 countries.

Zoltán-István SzabóDepartment of Pharmaceutical Industry and Management, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, Gh. Marinescu 38, RO-540139, Targu Mures, Romania.
György OrbánDepartment of Pharmaceutical Chemistry, Semmelweis University, Hőgyes E. u. 9, Budapest H-1092, Hungary.
Enikő BorbásDepartment of Organic Chemistry and Technology, Budapest University of Technology and Economics, Műegyetem rakpart 3., Budapest, H-1111, Hungary.
Dóra CsicsákDepartment of Pharmaceutical Chemistry, Semmelweis University, Hőgyes E. u. 9, Budapest H-1092, Hungary.
Szabina KádárDepartment of Organic Chemistry and Technology, Budapest University of Technology and Economics, Műegyetem rakpart 3., Budapest, H-1111, Hungary.
Béla FiserComputational Molecular Design Research Group, Institute of Chemistry, Faculty of Materials Science and Engineering, University of Miskolc, H-3515, Egyetemváros-Miskolc, Hungary.
Máté DobóDepartment of Pharmaceutical Chemistry, Semmelweis University, Hőgyes E. u. 9, Budapest H-1092, Hungary.
Péter HorváthDepartment of Pharmaceutical Chemistry, Semmelweis University, Hőgyes E. u. 9, Budapest H-1092, Hungary.
Eszter KissDepartment of Pharmaceutical Chemistry, Semmelweis University, Hőgyes E. u. 9, Budapest H-1092, Hungary.
Lívia BudaiDepartment of Pharmaceutics, Semmelweis University, Hőgyes Endre u. 7, Budapest, H-1092 Hungary.
Judit DobosVichem Chemie Research Ltd, Hermann O. utca 15, H-1022, Budapest, Hungary.
Tamás PállaDepartment of Pharmaceutical Chemistry, Semmelweis University, Hőgyes E. u. 9, Budapest H-1092, Hungary.
László ŐrfiDepartment of Pharmaceutical Chemistry, Semmelweis University, Hőgyes E. u. 9, Budapest H-1092, Hungary.
Gergely VölgyiDepartment of Pharmaceutical Chemistry, Semmelweis University, Hőgyes E. u. 9, Budapest H-1092, Hungary.
Gergő TóthDepartment of Pharmaceutical Chemistry, Semmelweis University, Hőgyes E. u. 9, Budapest H-1092, Hungary.
Semmelweis University · HUBudapest University of Technology and Economics · HUUniversitatea de Medicină, Farmacie, Științe și Tehnologie „George Emil Palade” din Târgu Mureș · ROUniversity of Miskolc · HUVichem Chemie (Hungary) · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pomalidomide (POM), a potent anticancer thalidomide analogue was characterized in terms of cyclodextrin complexation to improve its aqueous solubility and maintain its anti-angiogenic activity. The most promising cyclodextrin derivatives were selected by phase-solubility studies. From the investigated nine cyclodextrins - differing in cavity size, nature of substituents, degree of substitution and charge - the highest solubility increase was observed with sulfobutylether-β-cyclodextrin (SBE-β-CD). The inclusion complexation between POM and SBE-β-CD was further characterized with a wide variety of state-of-the-art analytical techniques, such as nuclear magnetic resonance spectroscopy (NMR), infrared spectroscopy (IR), circular dichroism spectroscopy, fluorescence spectroscopy as well as X-ray powder diffraction method (XRD). Job plot titration by NMR and the A

Indexed as

Comparative dissolutionCyclodextrin complexationInclusion complexPomalidomidePomalyst®Solubility

Identifiers

PMID34355087
PMCPMC8321930
OpenAlexW3184631791

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.